By Professor David Thomas

Book Chapters

Lin FP; Tran M; Thavaneswaran S; Grady JP; Kansara M; Chan J; Ballinger ML; Simes J; Thomas DM, 2025, 'Automating Precision Oncology Literature Curation: A Decision Tree Approach Using Large Language Models', in , pp. 248 - 252, http://dx.doi.org/10.3233/SHTI250839

Neuhaus SJ; Thomas DM, 2017, 'Multidisciplinary approach to treatment: An Australian perspective', in Sarcoma: A Multidisciplinary Approach to Treatment, Springer, pp. 461 - 476, http://dx.doi.org/10.1007/978-3-319-43121-5_23

Thomas DM; Whelan J, 2017, 'Bone Sarcomas in the Adolescent and Young Adult Population', in Bleyer A; Barr R; Ries L; Whelan J; Ferrari A (ed.), Cancer in Adolescents and Young Adults., Springer, pp. 417 - 427, http://dx.doi.org/10.1007/978-3-319-33679-4_16

Orme LM; Palmer S; Thomas D, 2009, 'No-man’s land: Between paediatric and adult medical oncology', in When Cancer Crosses Disciplines A Physician S Handbook, pp. 885 - 906, http://dx.doi.org/10.1142/9781848163652_0035

Thomas D, 2007, 'Fīrūzkūh: The summer capital of the Ghurids', in Cities in the Pre Modern Islamic World the Urban Impact of Religion State and Society, pp. 115 - 144, http://dx.doi.org/10.4324/9780203946473

Journal articles

Jaratlerdsiri W; Soh PXY; Gong T; Jiang J; Simayi Z; Petersen DC; Holland E; Chan EKF; Theron KE; Haacke WHG; Förtsch HEA; Bornman MSR; Thomas DM; Mphahlele J; Hayes VM, 2026, 'A catalogue of early diverged contemporary human genome variation reveals distinct Khoe-San populations', Nature Communications, 17, http://dx.doi.org/10.1038/s41467-026-69269-4

Dwarte TM; Alli R; Srinivasa S; Noon F; Perera Kimmantudawage S; Gordon L; Beshay V; Joshua AM; Ruiz Araujo R; Jalilian C; Thomas DM; Smith MJ; Winship I; Ballinger ML; Li M; Tucker KM; Courtney EK, 2026, 'Challenging interpretation of low-level PTCH1 mosaicism in patients with clinically diagnosed Gorlin syndrome: a case series and review of the literature', Hereditary Cancer in Clinical Practice, 24, http://dx.doi.org/10.1186/s13053-026-00332-3

Lin FP; Simes J; Thomas DM, 2026, 'Considerations in Genomic Therapy Matching-Reply', JAMA Oncology, 12, pp. 1036 - 1037, http://dx.doi.org/10.1001/jamaoncol.2026.2254

Lefkovits YR; McLean LS; Middleton MR; Thomas DM, 2026, 'BRAF-targeted therapy in non-melanomatous BRAF-mutant tumours: a systematic review of broad but histology-modulated efficacy', International Journal of Clinical Oncology, 31, pp. 1500 - 1515, http://dx.doi.org/10.1007/s10147-026-03079-y

Nagrial A; Carlino MS; Gunjur A; Brown MP; Harris S; Underhill C; Zielinski R; Kee D; Lam WS; Chan H; Harrup R; So J; Collins IM; Michael M; Chionh F; Uy C; Mariadason J; Torres J; Ballinger ML; Grady JP; Tavancheh E; Palmer J; Thomas DM; Wilkie K; Cebon J; Klein O, 2026, 'Nivolumab and Ipilimumab Combination Treatment in Patients with Advanced Intrahepatic Cholangiocarcinoma and Gallbladder Cancer: Results from the Phase II MoST-CIRCUIT Trial', Clinical Cancer Research, 32, pp. 3203 - 3212, http://dx.doi.org/10.1158/1078-0432.CCR-25-4009

Aggerholm-Pedersen N; Handrup MM; Thomassen SB; Engelmann B; Kongstad KM; Jakobsen MV; Baad-Hansen T; Farholt S; Thomas D; Ejerskov C, 2026, 'Prevalence, treatment and survival of malignant peripheral nerve sheath tumor in the Danish neurofibromatosis type 1 population', Oncologist, 31, http://dx.doi.org/10.1093/oncolo/oyag255

Kong BY; Lin FP-Y; Espinoza D; Aberoumand M; Thavaneswaran S; Meniawy T; Desai J; Harrup R; Nayagam SS; Charakidis M; Cuff K; Sebastian L; Lee CK; Wheeler P; Kansara M; Grady JP; Thomas DM; Ballinger ML; Simes J; Goldstein D, 2026, 'Tucatinib and trastuzumab in advanced cancers with HER2 mutations or amplifications: a molecular screening and therapeutics (MoST) program substudy', npj Precision Oncology, http://dx.doi.org/10.1038/s41698-026-01590-z

McNamee N; Aref A; Poulos R; Craft G; Koh J; Xavier D; Singh A; Kansara M; Robinson P; Hains P; Ballinger M; Liu JJ; Thomas D; Reddel R, 2026, 'Abstract B051: Targeted proteomics for parallel ADC biomarker screening: a pilot feasibility study within an Australian precision oncology program', Clinical Cancer Research, 32, pp. b051 - b051, http://dx.doi.org/10.1158/1557-3265.d32026-b051

Woodford R; Lord S; Lin F; Papenfuss AT; Marschner I; Thomas D; Friedlander M; Scott C; Simes J; Lee CK, 2026, 'Enhancing Outcome Measurement in Oncology Clinical Trials Through Artificial Intelligence: A Scoping Review', JCO Clinical Cancer Informatics, 10, http://dx.doi.org/10.1200/CCI-26-00014

Kok PS; Chan B; Aberoumoud M; Zhang A; O’Byrne K; Thavaneswaran S; Lin F; Kansara M; Corpuz T; Wheeler P; Simes RJ; Thomas D; Lee CK, 2026, 'Phase II Trial of First-Line Durvalumab and Chemotherapy in Patients With Extra-Pulmonary Small Cell Carcinoma', Jto Clinical and Research Reports, 7, http://dx.doi.org/10.1016/j.jtocrr.2026.101014

Barjesteh van Waalwijk van Doorn-Khosrovani S; Olivier T; Thomas D, 2026, 'Bypassing the evidence pathway: World-first tumour-agnostic reimbursement for dual immunotherapy', European Journal of Cancer, 241, http://dx.doi.org/10.1016/j.ejca.2026.116785

Cote GM; Aberoumand M; Choy E; Sebastian L; Mazzola E; Grimison P; Merriam P; Ballinger M; Thavaneswaran S; Lin F; Grady JP; Millward M; Brown MP; Harrup R; Espinoza D; Demetri G; Littlefield BA; Simes RJ; George S; Thomas D, 2026, 'A Phase 2 Study of Eribulin in Patients with Metastatic Angiosarcoma and Epithelioid Hemangioendothelioma', Clinical Cancer Research, 32, pp. 2206 - 2213, http://dx.doi.org/10.1158/1078-0432.CCR-25-3362

Rafati M; Guenther LM; Egolf LE; Gianferante M; Kim J; Wang K; Zhu B; Spector LG; Anderson N; Janeway KA; Barkauskas DA; Hawkins DS; Patiño-Garcia A; Lupo PJ; Scheurer ME; Morton L; Armstrong GT; Sapkota Y; Gramatges MM; Serra M; Hattinger C; Scotlandi K; Andrulis IL; Wunder JS; Ballinger ML; Thomas DM; Yeager M; Dean M; Stewart DR; Vogt A; Liu J; Hicks BD; Huang WY; Landi MT; Lori A; Diver WR; Savage SA; Chanock SJ; Mirabello L, 2026, 'SMARCAL1 is a new osteosarcoma predisposition gene', Journal of the National Cancer Institute, 118, pp. 1120 - 1125, http://dx.doi.org/10.1093/jnci/djaf278

Lin FP; Thavaneswaran S; Grady JP; Napier CE; Kansara M; Sebastian L; Kee D; Desai J; Zaheed M; Chinchen S; Oakes SR; Blackburn J; Scott HS; Glover A; Fox SB; Goldstein D; Leo P; Amanuel B; Mersiades A; Millward M; Brown MP; Charakidis M; Pokorny AMJ; Craft P; Espinoza D; Grimison P; Harrup R; Joshua AM; O'byrne K; Lee CK; Cowley MJ; Ballinger ML; Simes J; Thomas DM, 2026, 'Genomic Therapy Matching in Rare and Refractory Cancers', JAMA Oncology, 12, pp. 458 - 467, http://dx.doi.org/10.1001/jamaoncol.2026.0127

Best MC; Descallar J; Simpson G; Napier CE; Bartley N; Ballinger ML; Goldstein D; Thomas DM; Tucker KM; Butow P, 2026, 'Impact of Spiritual Wellbeing in Advanced Cancer Patients Receiving Genomic Test Results', Psycho Oncology, 35, pp. e70471, http://dx.doi.org/10.1002/pon.70471

Thomas DM; Kim JE; Barlesi F; Martens UM; Krzakowski M; Dziadziuszko R; Jeong JH; Daniele G; Wilson TR; Wu F; Simmons BP; Patel S; Sbirnac M; Kaul M; Gadgeel SM, 2026, 'TAPISTRY: A Phase II Study of Atezolizumab in Patients with Tumor Mutational Burden–High Tumors', Clinical Cancer Research, 32, pp. 1078 - 1086, http://dx.doi.org/10.1158/1078-0432.CCR-25-3336

Koh B; Thavaneswaran S; Lin F; Grady J; Maddula M; Haghighi KS; Kansara M; Huang ML; Ballinger ML; Simes J; Thomas DM; Goldstein D, 2026, 'Exceptional Response to Durvalumab and Tremelimumab in Pancreatic Acinar Cell Carcinoma With Ultramutated Phenotype Associated With a DNA Polymerase-ε Mutation', JCO Precision Oncology, 10, http://dx.doi.org/10.1200/PO-25-01003

Carlino MS; Gao B; Michael M; Marshall H; Gunjur A; Chan H; Zielinski R; So J; Harris SJ; Kee D; Collins IM; Lam WS; Lyle M; Underhill C; Brown MP; Harrup R; Wong SF; Grady J; Ballinger M; Tavancheh E; Thomas DM; Palmer J; Wilkie K; Cebon J; Klein O, 2026, 'Nivolumab and Ipilimumab in Advanced Mismatch Repair–Deficient/Microsatellite Instability–High Noncolorectal Cancers: A Nonrandomized Clinical Trial', JAMA Oncology, 12, pp. 39 - 47, http://dx.doi.org/10.1001/jamaoncol.2025.4721

Zaheed M; Signal B; Hooshmand K; Walwyn K; Tucker K; Ballinger ML; Thomas DM, 2026, 'Clinically actionable cancer and non-cancer risk genes identified by whole genome sequencing (WGS) in early-onset tumours (EOT).', Journal of Clinical Oncology, 44, pp. 170 - 170, http://dx.doi.org/10.1200/JCO.2026.44.19_suppl.170

Charakidis M; Waran H; Lau YM; Thomas D; Sebastian L; Toombs M, 2026, 'From exclusion to engagement and enrolment: single institutional experience of recruiting Aboriginal and Torres Strait Islander peoples for a genomic sequencing study', Internal Medicine Journal, http://dx.doi.org/10.1111/imj.70620

Siu DHW; Lin FPY; Thomas DM; Thavaneswaran S; Espinoza D; Chinchen S; Ballinger ML; Simes RJ; Lee CK, 2026, 'Time-to-progression ratio as a potential study endpoint in early-phase oncology trials: pooled analysis of phase II trials from the Australian MoST program', Future Oncology, 22, pp. 1965 - 1974, http://dx.doi.org/10.1080/14796694.2026.2688570

Southi N; Sim H-W; Grady J; Ballinger M; Thomas D; Thavaneswaran S, 2026, '145P Characterising homologous recombination deficiencies in gliomas', ESMO Open, 11, pp. 106288 - 106288, http://dx.doi.org/10.1016/j.esmoop.2026.106288

Srinivasa S; Fletcher C; Zhang BY; Goodwin A; Palme CE; Bhadri VA; Grimison PS; Thomas DM; Maclean F; Gupta R; Connolly EA, 2026, 'Corrigendum to ‘EP300::VGLL3 rhabdomyosarcoma: a potential distinct indolent adult rhabdomyosarcoma subtype’: [ESMO Rare Cancers, Volume 2, 100012]', ESMO Rare Cancers, pp. 100543, http://dx.doi.org/10.1016/j.esmorc.2026.100543

Lacaze P; Tiller J; Brotchie A; Nguyen-Dumont T; Steen J; Belluoccio D; Young M-A; Willis AM; Mitchell LA; Terrill B; Nowak KJ; Burns B; Horton AE; Nicholls SJ; Ademi Z; Green RC; Manchanda R; Thompson BA; Thomas D; Milne RL; Bruinsma F; Delatycki MB; Pang J; Watts GF; Macrae F; Poplawski N; Kirk J; Tucker K; Andrews L; Wallis M; Susman R; Pachter N; Sullivan D; Ragunathan A; James P; Zalcberg J; McNeil JJ; Southey MC; Winship I, 2026, 'Feasibility and outcomes of the DNA Screen nationwide adult genomic screening pilot', Nature Health, 1, pp. 90 - 98, http://dx.doi.org/10.1038/s44360-025-00020-x

Serrano C; Bauer S; Blay JY; Casali PG; Cicala CM; Dei Tos AP; Digklia A; Gelderblom H; Italiano A; Jones RL; Kasper B; Kyriazoglou A; Le Loarer F; Martín-Broto J; Napolitano A; Rutkowski P; Stacchiotti S; Tap W; Thomas D; Thway K; Valverde C; van der Graaf WTA; Wardelmann E; Bovée JVMG, 2025, 'Guidelines for Next-Generation Sequencing in Sarcoma Diagnosis and Treatment A Consensus Review', JAMA Oncology, 11, pp. 1527 - 1537, http://dx.doi.org/10.1001/jamaoncol.2025.3608

Jung MS; Poltavets V; Skhinas JN; Tax G; Kamili A; Xie J; Ghamrawi S; Graber P; Mao J; Wong-Erasmus M; Cui L; Kimpton K; Venkat P; Mayoh C; Lin A; Fleuren EDG; Fordham AM; Barger Z; Grady J; Thomas DM; Du EY; Graf NS; Cowley MJ; Gifford AJ; Fletcher JI; Lau LMS; Dolman MEM; Gooding JJ; Kavallaris M; Dolman E; Hearn B, 2025, 'High-throughput 3D engineered paediatric tumour models for precision medicine', Molecular Systems Biology, 21, pp. 1748 - 1777, http://dx.doi.org/10.1038/s44320-025-00152-y

Thavaneswaran S; Lin F; Espinoza D; Grady J; Kok PS; Chinchen S; Pavlakis N; Andelkovic V; Charakidis M; Craft P; Brown M; Desai J; Lau P; Kansara M; Simes J; Thomas D, 2025, 'A signal-seeking phase 2 study of tremelimumab in advanced cancers with high tumour mutational burden', Npj Precision Oncology, 9, http://dx.doi.org/10.1038/s41698-025-01156-5

Liang S; Kennedy E; Gale N; Watson P; Ramanathan M; Shinde A; McKay S; Torres-Robles A; Li Z; Chan J; Jones H; Ballinger ML; Butow P; Goldstein D; Leaney K; Middleton S; Morrow A; Thomas DM; Tucker KM; Zaheed M; Parkinson B; Lin F; Taylor N; Torres Robles A, 2025, 'Implementation of precision medicine in treating non-communicable diseases: a systematic review', Journal of Translational Medicine, 23, pp. 1174, http://dx.doi.org/10.1186/s12967-025-07201-y

Gheybi K; Soh PXY; Jiang J; Mbeki TMN; Louw M; Burns D; Mundra P; Kiriy D; Hasan MM; Jaratlerdsiri W; Lebelo MT; Campbell RA; Radzuma MB; Nenzhelele M; Obida M; Obida M; Ombuki WM; Oyaro MO; Patrick SM; Loda M; Wedge DC; Bristow RG; Brewer DS; Cooper CS; Reimand J; Cancel-Tassin G; Cussenot O; Hovens CM; Cocoran NM; Stricker PD; Schlomm T; Prins GS; Sørensen KD; Zanettini C; Yamaguchi TN; Xu Y; Uhrig S; Sahli A; Robinson B; Rausch T; Queiroz LR; Pope B; Pellegrina D; Papenfuss AT; Molania R; Marchionni L; Lutsik P; Leeman G; Lamy P; Khani F; Jung CH; Jaratlersiri W; Jakobsdottir GM; Imada EL; He HH; Hayes VM; Hamid A; Gruber AJ; Gnanapragasam VJ; Girma EG; Gihawi A; Gerhauser C; Favero F; Corcoran NM; Cheng KCL; Butler A; Brors B; Brook MN; Bova GSS; Zhou K; Yienya A; Wanjiku GS; Walong EOO; Walker DI; Uthayopas K; Tapinos A; Stellmacher G; Shirinde J; Oyieko W; Nyaga ME; Menoe R; Maendo U; Kote-Jarai Z; Huang R; Holmes V; Gong T; Gamxamub J; Förtsch HEA; Jensby EF; Fanelli GN; Craddock J; Birch L; Barnhoorn IEJ; Argos M; Madueke IC; Moreira DM; Ngugi PM; Bornman MSR; Weischenfeldt J; Mutambirwa SBA, 2025, 'Pathogenic variants reveal candidate genes for prostate cancer germline testing for men of African ancestry', Nature Communications, 16, http://dx.doi.org/10.1038/s41467-025-63865-6

van der Graaf WTA; Heiss NS; Hynes CL; Keller SP; Weinman A; Blay JY; Franco P; Giles RH; Lacombe D; Schlatter P; Thomas DM; van Waalwijk van Doorn-Khosrovani SB; Williamson M; Plummer R, 2025, 'Overcoming the barriers to treatment of rare cancer patients in the era of precision oncology: A call to action', Cancer Treatment Reviews, 140, http://dx.doi.org/10.1016/j.ctrv.2025.103013

Liang S; McKay S; Lin F; Zaheed M; Morrow A; Douglas B; Chan J; Monaghan H; Chan P; Kennedy E; Tyedmers E; Walker S; Leaney K; Napier CE; Middleton S; Butow P; Williams R; Parkinson B; Ballinger ML; Tucker K; Goldstein D; Thomas D; Taylor N, 2025, 'Integration of precision medicine into routine cancer care—protocol for the Precision Care Initiative: a research programme of effectiveness-implementation hybrid trials', BMJ Open, 15, http://dx.doi.org/10.1136/bmjopen-2024-090270

Cai Z; Boys EL; Noor Z; Aref AT; Xavier D; Lucas N; Williams SG; Koh JMS; Poulos RC; Wu Y; Dausmann M; Mackenzie KL; Aguilar-Mahecha A; Armengol C; Barranco MM; Basik M; Bowman ED; Clifton-Bligh R; Connolly EA; Cooper WA; Dalal B; Defazio A; Filipits M; Flynn PJ; Dinny Graham J; George J; Gill AJ; Gnant M; Habib R; Harris CC; Harvey K; Horvath LG; Jackson C; Kohonen-Corish MRJ; Lim E; Liu J; Long GV; Lord RV; Mann GJ; McCaughan GW; Morgan L; Murphy L; Nagabushan S; Nagrial A; Navinés J; Panizza BJ; Samra JS; Scolyer RA; Souglakos J; Swarbrick A; Thomas D; Balleine RL; Hains PG; Robinson PJ; Zhong Q; Reddel RR, 2025, 'Federated Deep Learning Enables Cancer Subtyping by Proteomics', Cancer Discovery, 15, pp. 1803 - 1818, http://dx.doi.org/10.1158/2159-8290.CD-24-1488

Gao B; Carlino MS; Michael M; Underhill C; Marshall H; Gunjur A; So J; Kee D; Antill Y; Lam WS; Chan H; Harrup R; Hamilton A; Grady J; Ballinger M; Tavancheh E; Yoon WH; Palmer J; Thomas D; Wilkie K; Cebon J; Klein O, 2025, 'Nivolumab and Ipilimumab Combination Treatment in Advanced Ovarian and Endometrial Clear Cell Cancers: A Nonrandomized Clinical Trial', JAMA Oncology, 11, pp. 982 - 989, http://dx.doi.org/10.1001/jamaoncol.2025.1916

Thavaneswaran S; Sim HW; Grady J; Espinoza D; Huang ML; Lin F; McGrath M; Desai J; Charakidis M; Brown M; Kansara M; Simes J; Thomas D, 2025, 'A phase II trial of larotrectinib in tumors with NTRK fusions or extremes of NTRK mRNA overexpression identified by comprehensive genomic profiling', Oncologist, 30, http://dx.doi.org/10.1093/oncolo/oyae339

Connolly EA; Boye K; Bonvalot S; Kratz CP; Leithner A; Malkin D; Messiou C; Miah AB; Pantziarka P; Timmermann B; van der Graaf WTA; Thomas DM; Stacchiotti S, 2025, 'Genetic predisposition in sarcomas: clinical implications and management', Eclinicalmedicine, 83, http://dx.doi.org/10.1016/j.eclinm.2025.103203

Gadgeel SM; Fajardo O; Barlesi F; Eun Kim J; Kurzrock R; Thomas DM; Jagtiani R; Noe J; Schwemmers S; Nikolaidis C, 2025, 'Real-world characteristics and survival outcomes of patients with metastatic ALK fusion-positive solid tumors treated with standard-of-care therapies', Oncologist, 30, http://dx.doi.org/10.1093/oncolo/oyaf005

McParland K; Koh ES; Kong B; Sim HW; Thavaneswaran S; Yip S; Barnes EH; Ballinger ML; Thomas DM; De Abreu Lourenco R; Simes J; Sebastian L; Wheeler PJ; Spyridopoulos D; Hawkins C; Pitz M; O'Callaghan C; Gan HK, 2025, 'Low & Anaplastic Grade Glioma Umbrella Study of MOlecular Guided TherapieS (LUMOS-2): study protocol for a phase 2, prospective, multicentre, open-label, multiarm, biomarker-directed, signal-seeking, umbrella, clinical trial for recurrent IDH mutant, grade 2/3 glioma', BMJ Open, 15, http://dx.doi.org/10.1136/BMJOPEN-2024-087922

Novis E; Glover A; Grady JP; Silvestri A; Thavaneswaran S; Lin F; Ballinger ML; Thomas DM, 2025, 'Oncogenic mutations in the TP53 and PI-3 kinase/AKT pathway are independent predictors of survival for advanced thyroid cancer: Analysis from the Molecular Screening and Therapeutics (MoST) program', Surgery United States, 177, http://dx.doi.org/10.1016/j.surg.2024.05.058

Ballinger ML; Thomas DM, 2025, 'POT1 clinical risk management is an open question', European Journal of Human Genetics, 33, pp. 3 - 4, http://dx.doi.org/10.1038/s41431-024-01676-x

Horgan D; Tanner M; Aggarwal C; Thomas D; Grover S; Basel-Salmon L; Dienstmann R; Tan TJY; Park WY; Abu Rasheed HM; Siu LL; Ma B; Ortiz-López R; Van Den Bulcke M; Taucher SC; Ferris A; Starling N; Malapelle U; Longshore J; Saldaña HAB; Subbiah V, 2025, 'Precision Oncology: A Global Perspective on Implementation and Policy Development', JCO Global Oncology, 11, http://dx.doi.org/10.1200/GO-24-00416

Kansara M; Thavaneswaran S; Lin FP; Kok P-S; Grady J; Thomas H; Corpuz T; Mundra P; Lu J; Ballinger M; Desai J; Harrup RA; Craft P; Charakidis M; O'Byrne KJ; Selva-Nayagam S; Millward M; Grimison P; Simes J; Thomas D, 2025, '1544P A phase II trial of palbociclib and avelumab in advanced solid tumours with CDK4/6 pathway alterations', Annals of Oncology, 36, pp. s922 - s923, http://dx.doi.org/10.1016/j.annonc.2025.08.2175

Kok PS; Chan B; Zhang A; O'Byrne K; Aberoumoud M; Thavaneswaran S; Lin FP; Kansara M; Corpuz T; Wheeler P; Simes J; Thomas DM; Lee CK, 2025, '181P Phase II trial of first-line durvalumab and chemotherapy in patients with extra-pulmonary small cell carcinoma', Annals of Oncology, 36, pp. s1816, http://dx.doi.org/10.1016/j.annonc.2025.10.1018

Kansara M; Lin FP; Thavaneswaran S; Huang ML; Tran M; Corpuz T; Lu J; Espinoza D; Chinchen S; Ballinger M; Grimison P; Andelkovic V; Dow EG; Desai J; Simes J; Thomas D, 2025, '2715P Phase II trial of tildrakizumab in treatment-refractory bone and soft tissue sarcomas', Annals of Oncology, 36, pp. s1447, http://dx.doi.org/10.1016/j.annonc.2025.08.3325

Gaughran G; Zaheed M; Harris SJ; Napier C; Yap M; Bellinger M; Grady J; Kee D; Caillet V; Davies A; Thavaneswaran S; Thomas DM, 2025, '777P HIF2α pathway aberrations across tumour types: A rare but actionable entity with high germline conversion', Annals of Oncology, 36, pp. s1990, http://dx.doi.org/10.1016/j.annonc.2025.10.1192

Gaughran G; Mamrot J; Fitzgerald S; Kee D; Napier C; Harris SJ; Thavaneswaran S; Grady J; Davies A; Bellinger M; Thomas DM, 2025, '797P Real-world experience of liquid biopsy (LBx) vs tissue-based comprehensive genomic profiling (tCGP)', Annals of Oncology, 36, pp. s1995 - s1996, http://dx.doi.org/10.1016/j.annonc.2025.10.1211

Back to profile page